Patent intelligence · US
US 12227581
Anti-BCMA single domain antibodies and application thereof
Anti-BCMA single domain antibodies and application thereof
Patent details — US 12227581
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 18, 2025
- Expiration
- Feb 13, 2045
- Applicant
- SHENZHEN PREGENE BIOPHARMA CO., LTD.
- Claims
- 11
- CPC classes
- A61K, A61K40/11, A61K40/31, A61K40/4215
Quick answer
US 12227581 (Anti-BCMA single domain antibodies and application thereof) is held by SHENZHEN PREGENE BIOPHARMA CO., LTD.. Status: granted. Granted Feb 18, 2025. Expires Feb 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SHENZHEN PREGENE BIOPHARMA CO., LTD.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K40/11, A61K40/31, A61K40/4215, A61K48/005, A61P
More from SHENZHEN PREGENE BIOPHARMA CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 12227581?
US 12227581 (Anti-BCMA single domain antibodies and application thereof) is held by SHENZHEN PREGENE BIOPHARMA CO., LTD.. Status: granted. Granted Feb 18, 2025. Expires Feb 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12227581?
SHENZHEN PREGENE BIOPHARMA CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 12227581 expire?
Our index shows an expiration date of Feb 13, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.